Selected research
Industry Research
Antibody Oligonucleotide Conjugates(AOC) Drug Industry Research Report 2026
Market perspective
The global Antibody Oligonucleotide Conjugates(AOC) Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Antibody Oligonucleotide Conjugates(AOC) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Antibody Oligonucleotide Conjugates(AOC) Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Antibody Oligonucleotide Conjugates(AOC) Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Antibody Oligonucleotide Conjugates(AOC) Drug include Avidity Biosciences, Denali Therapeutics, Dyne Therapeutics, Gennao Bio, Tallac Therapeutics, ChainGen Bio and Ractigen Therapeutics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Antibody Oligonucleotide Conjugates(AOC) Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody Oligonucleotide Conjugates(AOC) Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody Oligonucleotide Conjugates(AOC) Drug Market by Company
Avidity Biosciences
Denali Therapeutics
Dyne Therapeutics
Gennao Bio
Tallac Therapeutics
ChainGen Bio
Ractigen Therapeutics
Antibody Oligonucleotide Conjugates(AOC) Drug Segment by Type
Antisense Oligonucleotide(ASO) Based
Aptamer Based
Small Interfering RNA(siRNA) Based
Antibody Oligonucleotide Conjugates(AOC) Drug Segment by Application
FSHD
DMD
DMI
Cancer
Antibody Oligonucleotide Conjugates(AOC) Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Oligonucleotide Conjugates(AOC) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Oligonucleotide Conjugates(AOC) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Oligonucleotide Conjugates(AOC) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody Oligonucleotide Conjugates(AOC) Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Antisense Oligonucleotide(ASO) Based
- Aptamer Based
- Small Interfering RNA(siRNA) Based
Applications
- FSHD
- DMD
- DMI
- Cancer
Companies covered
- Avidity Biosciences
- Denali Therapeutics
- Dyne Therapeutics
- Gennao Bio
- Tallac Therapeutics
- ChainGen Bio
- Ractigen Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antibody Oligonucleotide Conjugates(AOC) Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Antisense Oligonucleotide(ASO) Based
- 2.2.3 Aptamer Based
- 2.2.4 Small Interfering RNA(siRNA) Based
- 2.3 Antibody Oligonucleotide Conjugates(AOC) Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 FSHD
- 2.3.3 DMD
- 2.3.4 DMI
- 2.3.5 Cancer
- 2.4 Assumptions and Limitations
3 Antibody Oligonucleotide Conjugates(AOC) Drug Breakdown Data by Type
- 3.1 Global Antibody Oligonucleotide Conjugates(AOC) Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Antibody Oligonucleotide Conjugates(AOC) Drug Forecasted Market Size by Type (2027-2032)
4 Antibody Oligonucleotide Conjugates(AOC) Drug Breakdown Data by Application
- 4.1 Global Antibody Oligonucleotide Conjugates(AOC) Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Antibody Oligonucleotide Conjugates(AOC) Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antibody Oligonucleotide Conjugates(AOC) Drug Market Perspective (2021-2032)
- 5.2 Global Antibody Oligonucleotide Conjugates(AOC) Drug Growth Trends by Region
- 5.2.1 Global Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antibody Oligonucleotide Conjugates(AOC) Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Antibody Oligonucleotide Conjugates(AOC) Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Antibody Oligonucleotide Conjugates(AOC) Drug Market Dynamics
- 5.3.1 Antibody Oligonucleotide Conjugates(AOC) Drug Industry Trends
- 5.3.2 Antibody Oligonucleotide Conjugates(AOC) Drug Market Drivers
- 5.3.3 Antibody Oligonucleotide Conjugates(AOC) Drug Market Challenges
- 5.3.4 Antibody Oligonucleotide Conjugates(AOC) Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antibody Oligonucleotide Conjugates(AOC) Drug Players by Revenue
- 6.1.1 Global Top Antibody Oligonucleotide Conjugates(AOC) Drug Players by Revenue (2021-2026)
- 6.1.2 Global Antibody Oligonucleotide Conjugates(AOC) Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Antibody Oligonucleotide Conjugates(AOC) Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antibody Oligonucleotide Conjugates(AOC) Drug Head Office and Area Served
- 6.4 Global Antibody Oligonucleotide Conjugates(AOC) Drug Players, Product Type & Application
- 6.5 Global Antibody Oligonucleotide Conjugates(AOC) Drug Manufacturers Established Date
- 6.6 Global Antibody Oligonucleotide Conjugates(AOC) Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size (2021-2032)
- 7.2 North America Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2021-2026)
- 7.4 North America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antibody Oligonucleotide Conjugates(AOC) Drug Market Size (2021-2032)
- 8.2 Europe Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2021-2026)
- 8.4 Europe Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Oligonucleotide Conjugates(AOC) Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size (2021-2032)
- 10.2 South America Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2021-2026)
- 10.4 South America Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Oligonucleotide Conjugates(AOC) Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Antibody Oligonucleotide Conjugates(AOC) Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antibody Oligonucleotide Conjugates(AOC) Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Avidity Biosciences
- 12.1.1 Avidity Biosciences Company Information
- 12.1.2 Avidity Biosciences Business Overview
- 12.1.3 Avidity Biosciences Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.1.4 Avidity Biosciences Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.1.5 Avidity Biosciences Recent Developments
- 12.2 Denali Therapeutics
- 12.2.1 Denali Therapeutics Company Information
- 12.2.2 Denali Therapeutics Business Overview
- 12.2.3 Denali Therapeutics Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.2.4 Denali Therapeutics Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.2.5 Denali Therapeutics Recent Developments
- 12.3 Dyne Therapeutics
- 12.3.1 Dyne Therapeutics Company Information
- 12.3.2 Dyne Therapeutics Business Overview
- 12.3.3 Dyne Therapeutics Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.3.4 Dyne Therapeutics Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.3.5 Dyne Therapeutics Recent Developments
- 12.4 Gennao Bio
- 12.4.1 Gennao Bio Company Information
- 12.4.2 Gennao Bio Business Overview
- 12.4.3 Gennao Bio Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.4.4 Gennao Bio Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.4.5 Gennao Bio Recent Developments
- 12.5 Tallac Therapeutics
- 12.5.1 Tallac Therapeutics Company Information
- 12.5.2 Tallac Therapeutics Business Overview
- 12.5.3 Tallac Therapeutics Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.5.4 Tallac Therapeutics Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.5.5 Tallac Therapeutics Recent Developments
- 12.6 ChainGen Bio
- 12.6.1 ChainGen Bio Company Information
- 12.6.2 ChainGen Bio Business Overview
- 12.6.3 ChainGen Bio Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.6.4 ChainGen Bio Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.6.5 ChainGen Bio Recent Developments
- 12.7 Ractigen Therapeutics
- 12.7.1 Ractigen Therapeutics Company Information
- 12.7.2 Ractigen Therapeutics Business Overview
- 12.7.3 Ractigen Therapeutics Revenue in Antibody Oligonucleotide Conjugates(AOC) Drug Business (2021-2026)
- 12.7.4 Ractigen Therapeutics Antibody Oligonucleotide Conjugates(AOC) Drug Product Portfolio
- 12.7.5 Ractigen Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst